Organon & Co.
OGN
주식 순위
#4358
Organon & Co., a global pharmaceutical enterprise, is dedicated to developing... Organon & Co., a global pharmaceutical enterprise, is dedicated to developing and delivering a wide array of prescription therapies. Its women's health division features reproductive care products, encompassing birth control and fertility treatments, notably Nexplanon/Implanon, an extended-duration contraceptive. The company's biosimilars collection includes three immune-related medications (Brenzys, Renflexis, Hadlima) and two cancer therapies (Ontruzant, Aybintio). Additionally, Organon provides cardiovascular medications, such as cholesterol-reducing drugs (Zetia, Ezetrol, Vytorin, Inegy, Rosuzet, Zocor) and treatments for high blood pressure (Cozaar, Hyzaar). Their respiratory product line addresses asthma symptoms with brands like Singulair, Dulera, Zenhale, and Asmanex, and manages seasonal allergies through Singulair, Nasonex, Clarinex, and Aerius. Furthermore, their offerings extend to dermatological care (Diprosone, Elocon), bone strengthening (Fosamax), and non-narcotic pain relief (Arcoxia, Diprospan, Celestone). The portfolio also comprises Proscar for treating symptomatic benign prostatic hyperplasia and Propecia for combating male pattern hair loss. The company's products are primarily distributed to pharmaceutical wholesalers, retailers, medical facilities, government entities, and various managed healthcare organizations, including health maintenance organizations and pharmacy benefit managers. Organon & Co. was established in 2020 and is headquartered in Jersey City, New Jersey.
주가
$13.76
마지막 동기화: 2026-10-20
시가총액
$3.61B
변동 (1일)
0.07%
변동 (1년)
52.49%
국가
US
거래 Organon & Co. (OGN)
카테고리
Healthcare
Organon & Co. (OGN)의 매출
Jun 2026 기준 매출 TTM: $6.13B
Organon & Co.의 최신 재무 보고서에 따르면 회사의 현재 수익 (TTM)은 $6.13B입니다. 2024년에 회사는 $6.40B의 수익을 올렸으며 이는 2023년의 $6.26B 대비 증가입니다. 수익은 상품이나 서비스를 판매하여 얻은 총 수입을 의미합니다. 수익과는 달리 비용이 차감되지 않습니다.
Organon & Co.의 수익 기록 (2017 ~ 2026)
매년 말 매출
| 연도 | 매출 | 변화 |
|---|---|---|
| 2026 (TTM) | $6.13B | -1.43% |
| 2025 | $6.22B | -2.92% |
| 2024 | $6.40B | 2.24% |
| 2023 | $6.26B | 1.44% |
| 2022 | $6.17B | -2.06% |
| 2021 | $6.30B | -3.49% |
| 2020 | $6.53B | -16.01% |
| 2019 | $7.78B | -20.46% |
| 2018 | $9.78B | -6.89% |
| 2017 | $10.50B | 0.00% |
유사 기업 또는 경쟁사의 매출
| 회사 | 매출 | 매출 차이 | 국가 |
|---|---|---|---|
| $79.67B | 1,200.24% |
US
|
|
| $99.34B | 1,521.27% |
US
|
|
| $64.39B | 950.86% |
US
|
|
| $66.40B | 983.73% |
US
|
|
| $77.52B | 1,165.20% |
CH
|
